NDAINJECTIONINJECTABLE
Approved
Feb 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
5/8 — Partial
KENALOG-40 (triamcinolone acetonide) by Bristol Myers Squibb is corticosteroid hormone receptor agonists [moa]. First approved in 1965.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KENALOG-40 is a corticosteroid hormone receptor agonist administered via injection for anti-inflammatory and immunosuppressive indications. It works by binding glucocorticoid receptors to reduce inflammation and immune response. The product has been on the market since 1965 and remains a standard-of-care injection for various dermatologic, rheumatologic, and soft-tissue conditions.
$0.026BPart D
LOE ApproachingAs a legacy corticosteroid injectable approaching loss of exclusivity, the KENALOG-40 brand team likely operates as a lean, specialized unit focused on maintaining market share and managing generic erosion rather than driving growth.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
Started Oct 2020
40 enrolled
Drug-Drug Interaction
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
Started Mar 2018
325 enrolled
Macular EdemaRetinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Started Jan 2017
460 enrolled
Macular EdemaRetinal Vein Occlusion
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema
Started Nov 2015
0UveitisCystoid Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Started Jan 2015
46 enrolled
Macular EdemaRetinal Vein Occlusion
Worked on KENALOG-40 at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.